Application

INGREZZA

Neurocrine Biosciences, Inc.

Trademark/Service Mark Application, Principal Register

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97673825
Filing Date: 11/11/2022

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 97673825
MARK INFORMATION
*MARK \\TICRS\EXPORT18\IMAGEOUT 18\976\738\97673825\xml1 \ APP0002.JPG
SPECIAL FORM YES
USPTO-GENERATED IMAGE NO
LITERAL ELEMENT INGREZZA
COLOR MARK YES
COLOR(S) CLAIMED
(If applicable)
The color(s) pink, orange, white, and black is/are claimed as a feature of the mark.
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of a sequence of right pointing arrows colored pink on the left shading into orange outlined with white lines and the word "INGREZZA" in black. The other white in the mark is background and is not claimed as a feature.
PIXEL COUNT ACCEPTABLE YES
PIXEL COUNT 816 x 255
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Neurocrine Biosciences, Inc.
*MAILING ADDRESS 12780 El Camino Real
*CITY San Diego
*STATE
(Required for U.S. applicants)
California
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
92130
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical preparations for human use for schizophrenia, adjunctive treatment of schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and movement disorders, namely, Myoclonus, chorea associated with Huntington's Disease, Levodopa-induced dyskinesia, dyskinetic cerebral palsy, dystonia, and tics.
FILING BASIS SECTION 1(b)
ATTORNEY INFORMATION
NAME B. Brett Heavner
ATTORNEY DOCKET NUMBER 14640.1013
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME Finnegan, Henderson, Farabow, Garrett & Dunner LLP
STREET 901 New York Avenue NW
CITY Washington
STATE District of Columbia
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 20001
PHONE 202-408-4000
FAX 202-408-4400
EMAIL ADDRESS docketing@finnegan.com
OTHER APPOINTED ATTORNEY all the other attorneys of Finnegan, Henderson, Farabow, Garrett & Dunner LLP
CORRESPONDENCE INFORMATION
NAME B. Brett Heavner
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@finnegan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) teas-filing-receipts@finnegan.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 1
APPLICATION FOR REGISTRATION PER CLASS 350
*TOTAL FEES DUE 350
*TOTAL FEES PAID 350
SIGNATURE INFORMATION
SIGNATURE /David L. Bradfute/
SIGNATORY'S NAME David L. Bradfute, PhD, JD
SIGNATORY'S POSITION Vice President & Head, Intellectual Property
SIGNATORY'S PHONE NUMBER 202-408-4000
DATE SIGNED 11/11/2022
SIGNATURE METHOD Sent to third party for signature



PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Trademark/Service Mark Application, Principal Register

Serial Number: 97673825
Filing Date: 11/11/2022

To the Commissioner for Trademarks:

MARK: INGREZZA (stylized and/or with design, see mark)
The literal element of the mark consists of INGREZZA. The color(s) pink, orange, white, and black is/are claimed as a feature of the mark. The mark consists of a sequence of right pointing arrows colored pink on the left shading into orange outlined with white lines and the word "INGREZZA" in black. The other white in the mark is background and is not claimed as a feature.
The applicant, Neurocrine Biosciences, Inc., a corporation of Delaware, having an address of
      12780 El Camino Real
      San Diego, California 92130
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations for human use for schizophrenia, adjunctive treatment of schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and movement disorders, namely, Myoclonus, chorea associated with Huntington's Disease, Levodopa-induced dyskinesia, dyskinetic cerebral palsy, dystonia, and tics.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The owner's/holder's proposed attorney information: B. Brett Heavner. Other appointed attorneys are all the other attorneys of Finnegan, Henderson, Farabow, Garrett & Dunner LLP. B. Brett Heavner of Finnegan, Henderson, Farabow, Garrett & Dunner LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      901 New York Avenue NW
      Washington, District of Columbia 20001
      United States
      202-408-4000(phone)
      202-408-4400(fax)
      docketing@finnegan.com
The docket/reference number is 14640.1013.
B. Brett Heavner submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      B. Brett Heavner
       PRIMARY EMAIL FOR CORRESPONDENCE: docketing@finnegan.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): teas-filing-receipts@finnegan.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

Declaration Signature

Signature: /David L. Bradfute/   Date: 11/11/2022
Signatory's Name: David L. Bradfute, PhD, JD
Signatory's Position: Vice President & Head, Intellectual Property
Signatory's Phone Number: 202-408-4000
Signature method: Sent to third party for signature
Payment Sale Number: 97673825
Payment Accounting Date: 11/14/2022

Serial Number: 97673825
Internet Transmission Date: Fri Nov 11 15:14:40 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.X.X-2022111115144247642
5-97673825-8201093255fbe102f20ec6bd385b4
64963a702f18f4de8686da39fd49cc5a722-CC-1
4401804-20221111134251852795

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed